


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (currently amended): A compound of the formula:



in which;

- a)  $X^1$  is represented by cyano, halogen or haloalkyl,
- b)  $R^1$  and  $R^2$  are each independently represented by hydrogen or  $(C_1-C_6)$  alkyl, optionally substituted, one of  $R^1$  or  $R^2$  is represented by  $C_1-C_6$  alkyl which may be optionally substituted, and the other of  $R^1$  or  $R^2$  is represented by hydrogen or  $C_1-C_6$  alkyl which may be optionally substituted.
- c)  $Alk^1$  is represented by a  $C_1-C_2$  linear alkylene group, in which up to two hydrogen atoms are optionally replaced by a substituent selected from the group consisting of  $C_1-C_6$  alkyl optionally substituted, halogen, hydroxy, thiol, and cyano,
- d)  $n$  is represented by the integer 0 or 1,
- e)  $Y$  is represented by  $NX^2X^3$  or  $O-X^3$ ,
- f)  $X^2$  is represented by hydrogen or  $(C_1-C_6)$  alkyl optionally substituted,
- g)  $X^3$  is represented by
  - i. hydrogen,
  - ii.  $(C_1-C_{12})$  alkyl, optionally substituted,
  - iii.  $(C_2-C_{12})$  alkenyl, optionally substituted,

- iv.  $(C_2-C_{12})$ alkynyl, optionally substituted,
- v.  $(C_3-C_{10})$ cycloalkyl, optionally substituted,
- vi.  $(C_3-C_{10})$  cycloalkyl( $C_1-C_6$ )alkyl, in which the alkyl and cycloalkyl moieties may each be optionally substituted,
- vii.  $(C_6-C_{10})$ aryl, optionally substituted,
- viii.  $(C_6-C_{10})$ aryl( $C_1-C_6$ )alkyl, in which the alkyl and aryl moieties may each be optionally substituted,
- ix.  $-(CH_2)-(Alk^2)_q-C(O)R^3$ , in which  $Alk^2$  is represented by a  $(C_1-C_8)$  linear alkylene group, in which up to eight hydrogen atoms may optionally be replaced by a substituent, selected from the group consisting of  $(C_1-C_6)$  alkyl optionally substituted,  $(C_1-C_6)$  alkoxy, halogen, hydroxy, thiol, cyano, and  $NR^8R^9$  in which  $R^8$  and  $R^9$  are each independently represented by hydrogen or  $(C_1-C_6)$  alkyl,  $q$  is the integer 0 or 1,  $R^3$  is represented by hydrogen,  $(C_1-C_{12})$ alkyl,  $(C_6-C_{10})$ aryl, or  $(C_6-C_{10})$ aryl( $C_1-C_6$ )alkyl, in which the alkyl and aryl moieties may each be optionally substituted,
- x.  $-(CH_2)-(Alk^2)_q-C(O)-O-R^4$ , in which  $Alk^2$  and  $q$ , are as defined above, and  $R^4$  is represented by hydrogen,  $(C_1-C_{12})$ alkyl,  $(C_6-C_{10})$ aryl, or  $(C_6-C_{10})$ aryl( $C_1-C_6$ )alkyl, in which the alkyl and aryl moieties may be optionally substituted,
- xi.  $-(CH_2)-(Alk^2)_q-C(O)-NR^5R^6$  in which  $Alk^2$  and  $q$  are as described above, and  $R^5$  and  $R^6$  are each independently represented by hydrogen,  $(C_1-C_{12})$ alkyl,  $(C_6-C_{10})$ aryl, or  $(C_6-C_{10})$ aryl( $C_1-C_6$ )alkyl, in which the alkyl and aryl moieties may be optionally substituted,
- xii.  $-(CH_2)-(Alk^2)_q-Y-R^7$ , in which  $Alk^2$  and  $q$  are as defined above,  $Y$  is O or S, and  $R^7$  is selected from the group consisting of hydrogen,  $(C_1-C_{12})$ alkyl,  $(C_6-C_{10})$ aryl, or  $(C_6-C_{10})$ aryl( $C_1-$

C<sub>6</sub>)alkyl, in which the alkyl and aryl moieties may be optionally substituted,

- xiii. heteroaryl, optionally substituted,
- xiv. heteroaryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, in which the heteroaryl and alkyl moieties may each be optionally substituted,
- xv. heterocyclic, optionally substituted,
- xvi. heterocyclic(C<sub>1</sub>-C<sub>6</sub>)alkyl, in which the alkyl and heterocyclic moieties may each be substituted, or,

h) for those compounds in which Y is N, X<sup>2</sup> and X<sup>3</sup>, along with the adjacent nitrogen atom, may form a heterocyclic ring, which may optionally be substituted, or a salt, or solvate, ~~or~~ prodrug thereof.

Claim 2 (original): A compound according to claim 1 in which one of R<sup>1</sup> or R<sup>2</sup> is hydrogen and the other of R<sup>1</sup> or R<sup>2</sup> is selected from the group consisting of isobutyl, propyl, n-butyl, isopropyl, and ethyl.

Claim 3 (currently amended): A compound according to claim ~~1~~ or 2 in which n is 0.

Claim 4 (currently amended): A compound according to claim ~~1, 2, or 3~~ in which X<sup>1</sup> is trifluoromethyl and is located at the 3-position of the phenyl ring.

Claim 5 (currently amended): A compound according to claim ~~1, 2, 3, or 4~~ in which Y is NX<sup>2</sup>X<sup>3</sup>.

Claim 6 (original): A compound according to claim 5 in which X<sup>2</sup> is hydrogen.

Claim 7 (original): A compound according to claim 6 in which X<sup>3</sup> is represented by a substituent selected from the group consisting of (C<sub>1</sub>-C<sub>12</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>6</sub>-C<sub>10</sub>)aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, heteroaryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, and heterocyclic(C<sub>1</sub>-C<sub>6</sub>)alkyl.

Claim 8 (currently amended): A compound according to claim 1, ~~2, 3, or 4~~ in which Y is  $OX^3$ .

Claim 9 (currently amended): A compound according to anyone of claim ~~[[s]] 1-8~~ in which  $X^1$  is represented by halogen or haloalkyl.

Claim 10-11 (canceled)

Claim 12 (currently amended): ~~Use of a compound according to anyone of claims 1-9 in the manufacture of a medicament for the~~ A method for alleviating a condition selected from the group consisting of hormone dependent cancers, benign hyperplasia of the prostate, acne, hirsutism, excess sebum, alopecia, premenstrual syndrome, lung cancer, precocious puberty, osteoporosis, hypogonadism, age-related decrease in muscle mass, and anemia ~~[[.]]~~

Claim 13 (currently amended): A pharmaceutical composition comprising a compound according to ~~anyone of claim~~ ~~[[s]] 1-9~~ in admixture with 1, or more, pharmaceutically acceptable excipients.

Claim 14 (currently amended): A topical pharmaceutical formulation comprising a compound according to ~~anyone of claim~~ ~~[[s]] 1-9~~ in admixture with 1, or more, pharmaceutically acceptable excipients suitable for dermal application.

Claim 15 (currently amended): ~~An article of manufacture~~ A kit comprising a compound according to ~~anyone of claim~~ ~~[[s]] 1-9~~ packaged for retail distribution, which advises a consumer how to utilize the compound to alleviate a condition selected from the group consisting of acne, alopecia, and oily skin.